Intersect ENT Inc (NASDAQ:XENT) insider Gwen R. Carscadden sold 10,000 shares of the firm’s stock in a transaction dated Friday, January 12th. The shares were sold at an average price of $34.35, for a total transaction of $343,500.00. Following the completion of the transaction, the insider now directly owns 13,856 shares in the company, valued at approximately $475,953.60. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.

Intersect ENT Inc (NASDAQ:XENT) traded down $0.55 during trading on Tuesday, reaching $33.80. 238,119 shares of the company traded hands, compared to its average volume of 325,090. Intersect ENT Inc has a twelve month low of $11.75 and a twelve month high of $35.34. The company has a market cap of $985.30, a price-to-earnings ratio of -54.52 and a beta of 0.67.

Intersect ENT (NASDAQ:XENT) last announced its earnings results on Thursday, November 2nd. The medical equipment provider reported ($0.15) EPS for the quarter, topping the consensus estimate of ($0.20) by $0.05. The firm had revenue of $22.31 million for the quarter, compared to the consensus estimate of $21.53 million. Intersect ENT had a negative net margin of 19.81% and a negative return on equity of 15.96%. The business’s quarterly revenue was up 20.8% on a year-over-year basis. During the same period last year, the company posted ($0.22) EPS. analysts predict that Intersect ENT Inc will post -0.63 EPS for the current fiscal year.

Several research analysts have recently issued reports on XENT shares. Zacks Investment Research lowered shares of Intersect ENT from a “buy” rating to a “hold” rating in a research note on Wednesday, November 1st. Guggenheim reissued a “buy” rating and set a $41.00 price objective on shares of Intersect ENT in a research note on Friday, December 15th. JPMorgan Chase & Co. raised shares of Intersect ENT from a “neutral” rating to an “overweight” rating in a research note on Tuesday, January 2nd. Canaccord Genuity reissued a “buy” rating and set a $36.00 price objective on shares of Intersect ENT in a research note on Monday, December 11th. Finally, BidaskClub lowered shares of Intersect ENT from a “hold” rating to a “sell” rating in a research note on Wednesday, December 20th. Five equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $33.38.

Hedge funds have recently made changes to their positions in the business. Oppenheimer Asset Management Inc. acquired a new stake in Intersect ENT during the 3rd quarter worth approximately $117,000. Great West Life Assurance Co. Can acquired a new stake in Intersect ENT during the 3rd quarter worth approximately $116,000. Legal & General Group Plc raised its holdings in Intersect ENT by 3.8% during the 2nd quarter. Legal & General Group Plc now owns 6,939 shares of the medical equipment provider’s stock worth $193,000 after buying an additional 255 shares during the period. Moors & Cabot Inc. acquired a new stake in Intersect ENT during the 2nd quarter worth approximately $205,000. Finally, Campbell & CO Investment Adviser LLC acquired a new stake in Intersect ENT during the 3rd quarter worth approximately $228,000. Hedge funds and other institutional investors own 86.31% of the company’s stock.

WARNING: This article was published by American Banking News and is the property of of American Banking News. If you are accessing this article on another domain, it was illegally stolen and republished in violation of United States & international copyright legislation. The original version of this article can be read at https://www.americanbankingnews.com/2018/01/16/insider-selling-intersect-ent-inc-xent-insider-sells-10000-shares-of-stock.html.

Intersect ENT Company Profile

Intersect ENT, Inc is a commercial-stage drug-device company. The Company develops drugs for patients with ear, nose and throat (ENT) conditions. The Company has developed a drug releasing bioabsorbable implant technology that enables targeted and sustained release of therapeutic agents. This targeted drug delivery technology is designed to allow ENT physicians to manage patient care.

Insider Buying and Selling by Quarter for Intersect ENT (NASDAQ:XENT)

Receive News & Ratings for Intersect ENT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intersect ENT and related companies with MarketBeat.com's FREE daily email newsletter.